WCN26-2413 SYNERGISTIC EFFECTS OF TRF-BUDESONID AND SPARSENTAN IN IGA-NEPHROPATHY

Read full text Summarise with VIRAT
Authors: Moritz Schanz, Leonie Kraft, Tina Oberacker, Severin Schricker, Joerg Latus
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sparsentan has emerged as a promising therapeutic option for IgA nephropathy (IgAN) while Targeted-release formulation (Trf-) Budesonid is an established treatment for patients with persistent proteinuria and evidence of inflammation. However, evidence regarding the sequential or combined use of both therapies in real-world settings remains scarce. In this subanalysis of our managed access program analysis for sparsentan, we present the 1-year follow-up of patients who received Trf-Budesonid prior, during, or after initiation of sparsentan.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104704–104704
Publication date
25 March 2026
Language
EN